Idorsia Ltd (IDIA.SW)

CHF 1.3

(2.45%)

Operating Expenses Summary of Idorsia Ltd

Idorsia Ltd's latest annual operating expenses in 2023 was 400.38 Million CHF , down -25.12% from previous year.
Idorsia Ltd's latest quarterly operating expenses in 2024 Q3 was 118 Million CHF , down -19.84% from previous quarter.
Idorsia Ltd reported a annual operating expenses of 893.8 Million CHF in annual operating expenses 2022, up 37.86% from previous year.
Idorsia Ltd reported a annual operating expenses of 648.35 Million CHF in annual operating expenses 2021, up 33.88% from previous year.
Idorsia Ltd reported a quarterly operating expenses of 97.29 Million CHF for 2024 Q1, down -26.11% from previous quarter.
Idorsia Ltd reported a quarterly operating expenses of 108.34 Million CHF for 2024 Q2, up 11.35% from previous quarter.

Annual Operating Expenses Chart of Idorsia Ltd (2023 - 2016)

Historical Annual Operating Expenses of Idorsia Ltd (2023 - 2016)

Year	Operating Expenses	Operating Expenses Growth
2023	400.38 Million CHF	-25.12%
2022	893.8 Million CHF	37.86%
2021	648.35 Million CHF	33.88%
2020	484.27 Million CHF	-4.34%
2019	506.24 Million CHF	17.27%
2018	431.69 Million CHF	176.88%
2017	155.91 Million CHF	-51.7%
2016	322.81 Million CHF	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q3	118 Million CHF	-19.84%
2024 Q1	97.29 Million CHF	-26.11%
2024 Q2	108.34 Million CHF	11.35%
2023 Q3	131.84 Million CHF	-34.92%
2023 FY	669.25 Million CHF	-25.12%
2023 Q1	217.76 Million CHF	-9.93%
2023 Q2	202.57 Million CHF	-6.97%
2023 Q4	131.68 Million CHF	-0.12%
2022 Q3	226.39 Million CHF	-0.66%
2022 FY	893.8 Million CHF	37.86%
2022 Q4	241.76 Million CHF	6.79%
2022 Q2	227.91 Million CHF	15.27%
2022 Q1	197.72 Million CHF	-15.25%
2021 FY	648.35 Million CHF	33.88%
2021 Q4	233.3 Million CHF	55.87%
2021 Q3	149.67 Million CHF	9.48%
2021 Q2	136.71 Million CHF	6.25%
2021 Q1	128.66 Million CHF	-0.85%
2020 FY	484.27 Million CHF	-4.34%
2020 Q3	118.16 Million CHF	-1.79%
2020 Q1	116.03 Million CHF	-11.57%
2020 Q2	120.31 Million CHF	3.69%
2020 Q4	129.76 Million CHF	9.82%
2019 Q2	127.13 Million CHF	1.48%
2019 Q1	125.27 Million CHF	-11.44%
2019 FY	506.24 Million CHF	17.27%
2019 Q4	131.21 Million CHF	7.02%
2019 Q3	122.61 Million CHF	-3.56%
2018 Q3	121.79 Million CHF	39.27%
2018 Q1	80.98 Million CHF	254.48%
2018 FY	431.69 Million CHF	176.88%
2018 Q4	141.46 Million CHF	16.15%
2018 Q2	87.45 Million CHF	7.98%
2017 FY	155.91 Million CHF	-51.7%
2017 Q1	111.52 Million CHF	0.0%
2017 Q2	-100.93 Million CHF	-190.51%
2017 Q4	22.84 Million CHF	-66.58%
2017 Q3	68.35 Million CHF	167.72%
2016 FY	322.81 Million CHF	0.0%

Peer Operating Expenses Comparison of Idorsia Ltd

Name	Operating Expenses	Operating Expenses Difference
Addex Therapeutics Ltd	11.89 Million CHF	-3266.172%
BB Biotech AG	-199.56 Million CHF	300.625%
Basilea Pharmaceutica AG	111.63 Million CHF	-258.652%
Evolva Holding SA	89.66 Million CHF	-346.541%
Kuros Biosciences AG	36.21 Million CHF	-1005.445%
Molecular Partners AG	20.3 Million CHF	-1872.126%
Relief Therapeutics Holding AG	114.94 Million CHF	-248.336%
Santhera Pharmaceuticals Holding AG	31.33 Million CHF	-1177.744%